Skip to content
Acceleron Pharma

Investors/Media

Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archived Events
Date Event Details
May 22, 2017
10:30 AM ET
UBS Global Healthcare Conference
May 8, 2017
8:00 AM ET
Acceleron Q1 Earnings Call
May 4, 2017
8:40 AM ET
Deutsche Bank 42nd Annual Health Care Conference
Apr 3, 2017
11:00 AM ET
Acceleron CMT Webinar
Mar 6, 2017
2:00 PM ET
Cowen and Company: 37th Annual Healthcare Conference
Mar 1, 2017
8:00 AM ET
Acceleron Q4 Earnings Call
Feb 21, 2017
Jefferies' Celgene Collaborators Summit

There will not be a webcast for this event.

Feb 16, 2017
1:00 PM ET
LEERINK Partners 6th Annual Global Healthcare Conference
Jan 9, 2017
2:00 PM PT
35th Annual J.P. Morgan Healthcare Conference
Dec 5, 2016
9:00 AM ET
ASH Data Review
Nov 7, 2016
3:30 PM MT
25th Annual Credit Suisse Healthcare Conference
Nov 3, 2016
5:00 PM ET
Acceleron Q3 Earnings Call
Oct 28, 2016
10:00 AM ET
Acceleron FSHD Webinar
Sep 12, 2016
3:40 PM ET
Morgan Stanley Global Healthcare Conference
Aug 4, 2016
8:00 AM ET
Acceleron Q2 Earnings Call
Jun 21, 2016
3:30 PM ET
JMP Securities Life Sciences Conference
Jun 10, 2016
8:00 AM ET
Acceleron EHA Congress Review
Jun 8, 2016
3:30 PM ET
Jefferies 2016 Healthcare Conference
May 23, 2016
3:00 PM ET
2016 UBS Global Healthcare Conference
May 5, 2016
10:00 AM ET
Deutsche Bank 41st Annual Health Care Conference
May 5, 2016
8:00 AM ET
Acceleron Q1 Earnings Call
Mar 17, 2016
11:15 AM ET
Barclays Global Healthcare Conference
Mar 9, 2016
Cowen and Company 36th Annual Health Care Conference
Mar 9, 2016
LEERINK Partners Annual Emerging Biotech Conference
Feb 25, 2016
Acceleron Q4 Earnings Call
Feb 23, 2016
SunTrust Robinson Humphrey 2016 Orphan Drug Day
Feb 10, 2016
LEERINK Partners 5th Annual Global Healthcare Conference
Dec 1, 2015
27th Annual Piper Jaffray Healthcare Conference
Nov 11, 2015
24th Annual Credit Suisse Healthcare Conference
Nov 4, 2015
Acceleron Q3 Earnings Call
Oct 23, 2015
Acceleron Pharma Inc. R&D Day
Sep 30, 2015
Leerink Partners 4th Annual Rare Disease Roundtable
Sep 18, 2015
Morgan Stanley Global Healthcare Conference 2015
Sep 10, 2015
Citi 10th Annual Biotech Conference
Aug 6, 2015
Acceleron Q2 Earnings Call
Jun 23, 2015
JMP Securities Life Sciences Conference
Jun 15, 2015
Acceleron European Hematology Association (EHA) Congress Review
Jun 1, 2015
Jefferies 2015 Global Healthcare Conference
May 20, 2015
UBS 2015 Global Healthcare Conference
May 12, 2015
Bank of America Merrill Lynch 2015 Health Care Conference
May 7, 2015
Deutsche Bank 40th Annual Health Care Conference
May 7, 2015
Acceleron Q1 Earnings Call
Mar 20, 2015
BioCentury 22nd Annual Future Leaders in the Biotech Industry
Mar 2, 2015
Acceleron Q4 Earnings Call
Mar 2, 2015
Cowen and Company 35th Annual Health Care Conference
Feb 28, 2015
ASCO Genitourinary Cancers Symposium 2015: Interview with Dr. Martin Voss of Memorial Sloan Kettering Cancer Center
Feb 24, 2015
RBC Capital Markets 2015 Healthcare Conference
Feb 11, 2015
2015 Leerink Global Healthcare Conference
Nov 7, 2012
Acceleron Recognized as Top 10 Venture-Backed Healthcare Start-Up Company by the Wall Street Journal
Sep 27, 2012
The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States

Click here for a link to the article

- Acceleron one of only two biopharmaceutical companies to make the list -

Cambridge, Mass. – September 27, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that it was recognized by the Wall Street Journal as one of the top 50 private venture-backed companies in the United States.  This is the second time that Acceleron was named to the list.

"Being recognized by the Wall Street Journal as one of the top 50 venture-backed companies in the U.S. is an honor and a great acknowledgement of our incredible employees, Board and partners, as well as the breakthrough science that serves as the foundation of our novel pipeline of products," said John Knopf, Ph.D., Chief Executive Officer of Acceleron. "Acceleron has recently made tremendous progress in advancing our pipeline of clinical-stage biologics and will deliver results from numerous Phase 2 clinical trials in 2013.  The next 12 months will be a transformative period in the evolution of the company."

Acceleron was selected for "The Next Big Thing – The Top 50 Venture-Backed Companies" based on criteria including fundraising success, recent growth in the company's value and the track record of its founders and board members. The editorial staff of Dow Jones VentureWire also reviewed and ranked the start-ups based on their knowledge of the companies' products, competition and financial performance. There were 5,900 companies considered for the ranking.

About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron's scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-β protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.

 

CONTACT:

Acceleron Pharma:
Steven Ertel, 617-649-9234
Chief Business Officer

Maureen L. Suda (Media)
Suda Communications LLC
585-387-9248

= add file to Briefcase